Want to join the conversation?
$CAH's Pharmaceutical segment continued its momentum into 1Q16, and the Medical segment strengthened its position in strategically critical areas. On a YoverY basis, Pharmaceutical segment posted 1Q16 revenue growth of 19% on growth from existing and new customers while Medical segment revenue grew marginally by 2%.
No better outlook on $MSFT. Even if the results beat a bit, the stock may move 4 to 6% higher, but won't go above $60.